A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening (NCT03806231), a randomized phase 3 study. The primary outcome is Dilation Completion Time.

2. Clinical Question

The broader study question also concerned maternal and newborn outcomes, healthcare-system cost, cost to the patient, and patient satisfaction. The stated hypotheses included lower overall encounter cost and greater satisfaction in the outpatient arm. These are planned questions, not findings: the trial was terminated before meeting the sample size considered sufficient for analysis, and the registry does not report results for these comparisons.

3. Trial Design

The registry describes a Phase 3, randomized, parallel-group trial with no masking. The two groups were outpatient cervical ripening and inpatient cervical ripening, each using dinoprostone. The stated purpose was to compare settings for pre-induction cervical ripening, rather than to compare different drugs. The protocol summary describes a randomized trial of 200 women, while the registry enrollment is 8. The record marks the trial as terminated; it does not state why it ended.

The trial began on 2019-08-07 and has a listed primary completion date of 2019-12-05. These dates describe the registry record and do not establish the reason for termination or the timing of any decision to stop. That reason is not reported in the registry record.

The outpatient arm’s description says participants would attend a scheduled Labor and Delivery visit before induction, receive the insert, and be monitored for 2 hours before being sent home. The inpatient arm’s description says participants would be admitted before induction, receive the insert, and have continuous fetal monitoring for 2 hours while remaining hospitalized. The available descriptions are truncated, so further operational details are not reported in the registry record.

Random allocation can help make groups comparable on average, but it does not guarantee balance in a small enrolled sample. With enrollment of 8 and no reported outcome analysis, randomization alone cannot support a reliable comparison of outcomes. No allocation procedure, concealment details, or analysis population is reported in the registry record. The record identifies 12 outcome measures and lists patient satisfaction, delivery mode, and several time intervals among secondary outcomes, but does not report comparative results for them.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Trial terminated prior to meeting sufficient sample size for analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Dilation Completion Time, measured over Time of admission to completion of dilation (up to 48 hours).

The primary endpoint is dilation completion time: the time from admission for induction to complete cervical dilation. Its stated timeframe is up to 48 hours. This is a time-to-event outcome: the event is completion of dilation, and the measured quantity is the elapsed time until that event. The registry’s description names the starting point and event, but does not give a unit, a summary measure, or a statistical parameter for the planned comparison.

As a general statistical matter, a time-to-event endpoint can retain information about when an event occurs, rather than reducing every participant’s experience to whether the event occurred by a single cutoff. This may be useful when the timing of labor progression is important to the research question. A participant who has not reached the event within the observation window may have incomplete event-time information; appropriate analysis depends on how such observations are handled and on the prespecified method. The analysis method and handling of incomplete observation are not reported in the registry record.

The investigators’ stated hypothesis was that the outpatient group would take less time from admission to complete dilation. The endpoint therefore addresses one aspect of the proposed comparison, but it does not by itself describe delivery mode, newborn outcomes, costs, or satisfaction. Those broader questions require their own outcome definitions and analyses. No endpoint values or group comparison are reported, so the registry record does not establish the direction or precision of any difference in dilation completion time.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

There are no reported comparative analyses to explain for this trial. The registry records 0 analyses and says the trial ended before meeting sufficient sample size for analysis. That means no reported estimate of the primary effect, uncertainty interval, or statistical test is available in the registry record. The methods concepts below describe how such results are generally interpreted; they are not claims about procedures used in this trial.

What does randomization contribute?

In general, randomization assigns participants to study groups by chance. Its purpose is to reduce systematic differences between groups at the start of a trial, including differences that investigators may not have measured. It does not guarantee that groups will be alike, particularly when enrollment is limited. Nor does randomization remove the need to report the allocation process, participant flow, outcome definitions, and statistical analysis. The registry identifies the design as randomized but does not report the sequence-generation or concealment methods.

How should a time-to-event outcome be analyzed?

In general, time-to-event analysis considers both whether an event occurred and when it occurred. For this trial, the event is complete cervical dilation, and the clock starts at admission for induction. If observation ends before a participant reaches the event, the event time is not fully observed. Statistical methods can account for such incomplete follow-up, but the choice depends on the study design and assumptions. The registry does not report whether any observations were incomplete, what method was planned, or how the stated up-to-48-hour window was incorporated.

Different summaries answer different questions. A comparison of average times, a comparison of event-time distributions, and a model-based time-to-event estimate need not have the same interpretation. The registry does not name a summary measure or model for the primary endpoint. Therefore, no particular analysis method should be attributed to the investigators. A confidence interval, when reported, helps show the range of uncertainty around an estimated comparison; no primary-outcome interval is present in this record.

Why do sample size and precision matter?

In general, sample size affects how much information a trial can provide. With limited observations, estimates may be imprecise and can vary substantially with the outcomes of individual participants. A nonsignificant test, if one had been reported, would not by itself show that groups were equivalent; equivalence requires a suitable design, margin, and analysis. No test result is reported for this trial, and the record explicitly says that the trial was terminated before the sample size was sufficient for analysis.

The registry’s planning-illustration description refers to two-sided significance level 0.05, equal allocation, a normal approximation, and effects expressed as fractions of an observed effect. It also distinguishes time-to-event planning in terms of total events from other planning in terms of participants per arm. These are general assumptions for illustrations, not evidence that the trial used them to plan its own enrollment. The record does not report the trial’s own sample-size justification or an observed effect on which to base a meaningful planning illustration.

What role do model assumptions play?

As a general matter, a statistical model links observed data to an estimate and relies on assumptions about the data. For count outcomes, over-dispersion means that variability exceeds what a basic count model expects; ignoring it can make uncertainty look too small. For time-to-event outcomes, assumptions can concern the event-time pattern and how incomplete observation relates to outcome risk. No count-model analysis, dispersion estimate, or primary-outcome model is reported for this trial, so these concepts cannot be used to infer a result.

Unadjusted re-calculations from summary statistics, when available, are not substitutes for a trial’s prespecified analysis. They may use less information than the original analysis and may not account for design features or covariates. No primary outcome summary statistics are posted for this trial, so a recalculated comparison is not available. There is also no sponsor analysis reported to compare against a recalculation.

How should safety counts be interpreted?

Safety counts describe recorded events and the number of participants listed as at risk. They do not by themselves establish that an event was caused by the intervention. A comparative safety analysis would need clear definitions, follow-up periods, and an appropriate measure of uncertainty. The registry lists the arm-level counts but does not report event descriptions, timing, causal assessments, or a statistical comparison. Given the limited enrollment and lack of outcome analysis, the counts should be read descriptively.

These general principles explain why the absence of a reported estimate is consequential. Statistical interpretation depends not only on the design label and the planned question, but also on outcome data, a defined analysis, and transparent reporting of uncertainty. In this record, the central result needed to answer the primary question is not reported in the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry identifies 12 outcome measures, including the primary dilation completion time and secondary outcomes covering satisfaction, delivery mode, and several time intervals. When a study examines multiple outcomes or multiple comparisons, the chance of observing an apparently notable result by chance can increase. As a general statistical principle, investigators may address this through a prespecified hierarchy, adjustment, or a clear distinction between primary and exploratory outcomes. The registry record does not report a multiplicity strategy, such as whether any adjustment was planned.

The record does not report an analysis population, participant flow by outcome, or a method for handling missing data. It therefore is not possible to determine which enrolled participants contributed to any particular endpoint, whether outcome data were unavailable, or whether any participants were excluded from an analysis. The primary outcome description states that the trial was terminated before reaching sufficient sample size for analysis, and no outcome analysis is reported.

These absences limit interpretation in different ways. Without a defined analysis population and missing-data approach, readers cannot assess whether the analyzed group would have preserved the randomized comparison or how incomplete outcome observation might affect estimates. Without a reported multiplicity approach, readers cannot evaluate how the many planned outcomes were to be interpreted together. These are not evidence of a specific flaw in conduct; they are details not reported in the registry record. The absence of results also means that no selective pattern of positive or negative findings can be assessed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry lists 4 participants at risk in each arm. It records 0 serious adverse events in the outpatient group and 0 in the inpatient group, with 0 deaths in either group. For other adverse events, it records 0 in the outpatient group and 1 in the inpatient group. These are registry counts; no comparative safety estimate or uncertainty interval is reported.

The entries do not identify the nature, timing, severity beyond the serious-versus-other classification, or assessed relationship of the other event to cervical ripening. They also do not state the duration or completeness of safety follow-up. A count of zero serious events in a small group does not establish that the risk is absent, and one recorded event does not establish that the intervention caused it. The event counts should therefore be treated as descriptive rather than as a reliable comparison between settings.

The record’s limited enrollment and lack of an outcome analysis further restrict what can be learned from these safety entries. They do not provide a basis for broad safety conclusions about outpatient or inpatient cervical ripening.

12. What the Result Does, and Does Not, Mean

The registry documents a randomized, parallel-group comparison of outpatient and inpatient dinoprostone cervical ripening before induction of labor. Its primary question concerned time from admission for induction to complete dilation, with observation described as up to 48 hours. The record also lists planned questions about maternal and newborn outcomes, cost, satisfaction, and additional labor and delivery time measures.

What the record does not establish is whether either approach shortened dilation time, changed delivery outcomes, reduced costs, or improved satisfaction. Enrollment is recorded as 8, the status is terminated, and the primary outcome description says the trial ended before meeting sufficient sample size for analysis. No comparative result, effect estimate, confidence interval, or test result is reported. A planned hypothesis is not a finding, and the fact that no analysis is posted is not evidence that the groups had identical outcomes.

The safety entries report no serious adverse events or deaths in either group and one other adverse event in the inpatient group. These descriptive counts cannot show whether the event was caused by the intervention or establish a difference in safety. They also cannot rule out events that were not captured or reported.

For readers, the useful distinction is between the research question and the evidence available to answer it. The trial record shows what was intended to be compared and records limited enrollment and safety counts. It does not provide the outcome data or analysis needed to estimate the primary comparison. The reason for termination, the detailed analysis plan, and the handling of incomplete data are not reported in the registry record. Conclusions about the relative effects of the two settings therefore remain unresolved by this record.

13. Why This Trial Matters Statistically

This trial illustrates the difference between a randomized design and an informative result. Random allocation is an important design feature, but it cannot compensate for the absence of an analyzable outcome comparison. The registry records enrollment of 8 and termination before the sample size considered sufficient for analysis. No estimate of the primary endpoint or its uncertainty is reported.

The distinction matters because statistical evidence is not conveyed by a trial’s hypothesis alone. The investigators expected outpatient ripening to reduce the time from admission to complete dilation, and also proposed differences in cost and satisfaction. Those statements describe the questions the trial was designed to investigate. Without reported outcome data and analysis, they cannot be treated as conclusions.

The record also demonstrates why transparent reporting of methods is important. Readers cannot evaluate an outcome comparison without knowing the analysis population, how incomplete observations were handled, or what statistical approach was used. In a trial with multiple outcomes, understanding the prespecified approach to multiplicity is also relevant. These details are not reported in the registry record, alongside the absence of primary results.

The safety counts provide another statistical lesson: event counts are not the same as evidence of a comparative risk. Zero recorded serious events in the listed groups does not establish zero risk, while a single other event does not establish a causal difference. Context, follow-up, definitions, and uncertainty all matter.

For clinical researchers and biostatisticians, the record is a reminder to distinguish design intent, conduct, and analyzed evidence. A well-defined clinical question can remain unanswered when a trial stops before the planned analysis can be supported. The registry communicates that limitation, but does not explain why termination occurred.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important trial-specific limitation is that the registry reports termination before the trial met sufficient sample size for analysis. Enrollment is recorded as 8, compared with the protocol summary’s planned 200 women. No primary-outcome estimate or comparative analysis is reported, so the intended question about dilation completion time cannot be answered from this record.

The reason for termination is not reported in the registry record. It is therefore not possible to determine whether recruitment challenges, operational issues, safety considerations, or another factor contributed. The record also does not explain whether the listed primary completion date reflects the end of recruitment, follow-up, or another milestone.

Descriptions of the intervention procedures are incomplete in the registry record. The outpatient and inpatient descriptions include monitoring for 2 hours, but the text ends before all procedural details are available. Further information about adherence, deviations from assigned setting, crossover, and follow-up is not reported. The record does not give participant characteristics, so it is not possible to assess how closely the enrolled group represents the intended population.

Statistical details are also limited. The randomization method, allocation concealment, analysis population, primary analysis method, multiplicity approach, and missing-data handling are not reported. The primary endpoint has no reported unit or statistical parameter. These omissions prevent assessment of how the planned comparison would have been estimated, even apart from the lack of results.

Finally, the safety information is sparse: event descriptions, timing, follow-up duration, and causal assessments are not reported. The counts should not be generalized beyond their descriptive role in this small, terminated trial.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening — NCT03806231.
• Registry record last updated 2021-09-05; status last verified 2021-08.
• Results first posted 2021-09-05.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes a Phase 3, randomized, unmasked, parallel-group trial comparing outpatient and inpatient dinoprostone cervical ripening before induction of labor. The intended population was women at 39.0-41.6 weeks gestation. The primary endpoint was time from admission for induction to complete cervical dilation, with a stated timeframe of up to 48 hours.

The protocol summary describes a trial of 200 women, while recorded enrollment is 8. The trial is marked terminated. The registry says it ended before meeting sufficient sample size for analysis and reports no comparative primary-outcome analysis. It lists 12 outcome measures, including satisfaction, delivery outcomes, and additional time intervals, but does not report comparative results for them.

Safety entries list 0 serious adverse events and 0 deaths in both arms, with 1 other adverse event in the inpatient group and none in the outpatient group. The reason for termination and detailed statistical methods are not reported in the registry record.